Withaferin-A

Withaferin-A (WA), the prototypical withanolide and the first member of the C28-ergostane steroidal lactone class to be structurally characterized, is a naturally occurring phytochemical isolated principally from the leaves and roots of Withania somnifera (Linnaeus) Dunal (Solanaceae), a plant used for millennia in Ayurvedic medicine under the common name ashwagandha. The compound was first isolated by Lavie and colleagues in 1965 from the leaves of Withania somnifera and Acnistus arborescens, and its structural elucidation established the withanolide class as a distinct group of naturally occurring steroidal lactones characterized by a C28-ergostane skeleton with an oxidized delta-lactone side chain formed between carbons 22 and 26 [1, 2]. The chemical reactivity of Withaferin-A derives from three electrophilic pharmacophores: the alpha,beta-unsaturated ketone in the A ring, the 5beta,6beta-epoxide in the B ring, and the unsaturated delta-lactone in the side chain, each capable of forming covalent adducts with nucleophilic cysteine residues on target proteins through Michael addition chemistry [3].

The molecular pharmacology of Withaferin-A is characterized by covalent, multi-target engagement. The compound binds covalently to the sole cysteine residue (Cys328 in human vimentin) in the alpha-helical coiled-coil 2B domain of the intermediate filament protein vimentin, inducing filament aggregation, disrupting cytoskeletal architecture, and inhibiting epithelial-to-mesenchymal transition in cancer cells [4, 5]. It inhibits NF-kappaB signaling by direct thioalkylation of IKKbeta, preventing IkappaB phosphorylation and nuclear translocation of the NF-kappaB p65/p50 heterodimer [6, 7]. It binds the C-terminal domain of Hsp90 through an ATP-independent mechanism, inducing proteasomal degradation of Hsp90 client proteins including Akt, Cdk4, and the glucocorticoid receptor [8]. Additional validated direct targets include annexin II, beta-tubulin, mortalin (mitochondrial Hsp70), KEAP1, and Bruton tyrosine kinase [3, 9]. The breadth of covalent target engagement produces convergent antiproliferative, pro-apoptotic, anti-angiogenic, and anti-inflammatory activity across multiple cancer cell lines and xenograft models.

Preclinical anticancer efficacy has been demonstrated in xenograft and orthotopic tumor models of breast cancer (including triple-negative breast cancer), ovarian cancer, cervical carcinoma, glioblastoma, pancreatic cancer, melanoma, neuroblastoma, and multiple myeloma, with tumor growth inhibition typically observed at intraperitoneal doses of 2 to 8 mg/kg in mice [10, 11, 12]. Beyond oncology, Withaferin-A has been characterized as a leptin sensitizer with strong antidiabetic and anti-obesity properties; treatment of diet-induced obese mice produced 20 to 25 percent reduction in body weight, reversal of hepatic steatosis, and normalization of glucose metabolism independently of the leptin-sensitizing effect [13]. Neuroprotective activity has been demonstrated in multiple rodent models.

Pharmacokinetics in rodents are characterized by low oral bioavailability (approximately 1.8 to 32 percent depending on formulation and species), rapid hepatic metabolism, and a short plasma half-life of approximately 1.36 hours in mice [14, 15]. The compound crosses the blood-brain barrier. The LD50 following oral administration in mice exceeds 2000 mg/kg body weight, placing Withaferin-A in GHS toxicity category 5 [16]. A Phase I dose-escalation clinical trial in patients with advanced-stage high-grade osteosarcoma (Pires et al. 2019) evaluated oral doses of 72, 108, 144, and 216 mg of Withaferin-A in the published literature and reported tolerability without dose-limiting toxicity; adverse events were limited to grade 1 and grade 2 severity, principally liver enzyme elevation and skin rash [17]. The maximum tolerated dose was not reached. Circulating Withaferin-A could not be quantified by the HPLC bioanalytical method employed, consistent with the low oral bioavailability observed in preclinical studies and representing a principal translational challenge. This monograph reviews the chemistry, isolation, and biosynthesis of Withaferin-A; the covalent multi-target pharmacology; the pharmacokinetic record; the preclinical efficacy across oncology, metabolic, and neurological models; the Phase I clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five natural-product anticancer and anti-inflammatory candidates against Withaferin-A on five competency standards.